Antibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations
- Flow cytometry [3]
Submit
Validation data
Reference
Comment
Report error
- Product number
- DM1228 - Provider product page
- Provider
- Acris Antibodies GmbH
- Proper citation
- Acris Antibodies GmbH Cat#DM1228, RRID:AB_10655158
- Product name
- anti CD66a/e (CEACAM1/5)
- Antibody type
- Monoclonal
- Antigen
- Immunisation with extracted protein of CEACAM5.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- 4/3/17
- Vial size
- 0.1 mg
- Concentration
- 1.0 mg/ml
Submitted references Neisseria meningitidis has two independent modes of recognizing its human receptor CEACAM1.
Lymphatic reprogramming of microvascular endothelial cells by CEA-related cell adhesion molecule-1 via interaction with VEGFR-3 and Prox1.
Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma.
Characterization of gastric adenocarcinoma cell lines established from CEA424/SV40 T antigen-transgenic mice with or without a human CEA transgene.
CEACAM1 functionally interacts with filamin A and exerts a dual role in the regulation of cell migration.
Establishment and phenotypic characterization of human U937 cells with inducible P210 BCR/ABL expression reveals upregulation of CEACAM1 (CD66a).
Homophilic adhesion of human CEACAM1 involves N-terminal domain interactions: structural analysis of the binding site.
Kuespert K, Roth A, Hauck CR
PloS one 2011 Jan 27;6(1):e14609
PloS one 2011 Jan 27;6(1):e14609
Lymphatic reprogramming of microvascular endothelial cells by CEA-related cell adhesion molecule-1 via interaction with VEGFR-3 and Prox1.
Kilic N, Oliveira-Ferrer L, Neshat-Vahid S, Irmak S, Obst-Pernberg K, Wurmbach JH, Loges S, Kilic E, Weil J, Lauke H, Tilki D, Singer BB, Ergün S
Blood 2007 Dec 15;110(13):4223-33
Blood 2007 Dec 15;110(13):4223-33
Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma.
Riesenberg R, Weiler C, Spring O, Eder M, Buchner A, Popp T, Castro M, Kammerer R, Takikawa O, Hatz RA, Stief CG, Hofstetter A, Zimmermann W
Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Dec 1;13(23):6993-7002
Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Dec 1;13(23):6993-7002
Characterization of gastric adenocarcinoma cell lines established from CEA424/SV40 T antigen-transgenic mice with or without a human CEA transgene.
Nöckel J, van den Engel NK, Winter H, Hatz RA, Zimmermann W, Kammerer R
BMC cancer 2006 Mar 14;6:57
BMC cancer 2006 Mar 14;6:57
CEACAM1 functionally interacts with filamin A and exerts a dual role in the regulation of cell migration.
Klaile E, Müller MM, Kannicht C, Singer BB, Lucka L
Journal of cell science 2005 Dec 1;118(Pt 23):5513-24
Journal of cell science 2005 Dec 1;118(Pt 23):5513-24
Establishment and phenotypic characterization of human U937 cells with inducible P210 BCR/ABL expression reveals upregulation of CEACAM1 (CD66a).
Håkansson P, Lassen C, Olofsson T, Baldetorp B, Karlsson A, Gullberg U, Fioretos T
Leukemia 2004 Mar;18(3):538-47
Leukemia 2004 Mar;18(3):538-47
Homophilic adhesion of human CEACAM1 involves N-terminal domain interactions: structural analysis of the binding site.
Watt SM, Teixeira AM, Zhou GQ, Doyonnas R, Zhang Y, Grunert F, Blumberg RS, Kuroki M, Skubitz KM, Bates PA
Blood 2001 Sep 1;98(5):1469-79
Blood 2001 Sep 1;98(5):1469-79
No comments: Submit comment
Supportive validation
- Submitted by
- Acris Antibodies GmbH (provider)
- Main image
- Experimental details
- Figure.1: FACS analysis of BOSC23 cells using 4/3/17 antibody (Cat.#DM1228). BOSC23 cells were transiently transfected with anexpression vector encoding either CEACAM1 (Red curve) oran irrelevant protein (control transfectant). Binding of 4/3/17 was detected with a PE conjugated secondary antibody. A positive signal was obtained only with CEACAM1 transfected cells.
- Submitted by
- Acris Antibodies GmbH (provider)
- Main image
- Experimental details
- Figure.2: FACS analysis of BOSC23 cells using 4/3/17 antibody (Cat.#DM1228). BOSC23 cells were transiently transfected with anexpression vector encoding either CEACAM5 (Red curve) oran irrelevant protein (control transfectant). Binding of 4/3/17 was detected with a PE conjugated secondary antibody. A positive signal was obtained only with CEACAM5 transfected cells.
- Submitted by
- Acris Antibodies GmbH (provider)
- Main image
- Experimental details
- Figure.3: Specificity testing of 4/3/17. BOSC cells were transiently transfected with expression vectors containing either the cDNA of CEACAM1, 3, 5, 6, 8 or are combinant transmembrane-anchored PSG1 fusion protein. Expression of the constructs was confirmed with monoclonal antibodies known to recognise the corresponding proteins (CEACAM1, 3, 5 and 6: D14HD11; CEACAM8: 80H3;PSG: BAP1; Green curves). An irrelevant monoclonal antibody served as a negative control (black curves). For specificity testing, protein G purified 4/3/17 was tested on all CEACAM transfectants. A positive signal was obtained with CEACAM1 and CEACAM5 expressing cells (Red curves).